Subscribe
Halawi / Shutterstock.com
13 August 2024NewsBig PharmaSarah Speight

Novartis fails to block first heart-failure generic by Indian rival

Delaware judge denies pharma giant’s request for injunction on rivals’ generic of Entresto | Novartis ‘unlikely to succeed’ in proving infringement | Lawsuit is one of several attempts to preserve exclusivity of the drug ahead of patent expiry and US price caps.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Novartis vows to challenge heart drug patent loss
11 July 2023   Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.
Generics
Novartis sued over blockbuster heart failure drug
30 August 2022   Pharma company facing lawsuit from two universities | Dispute centres on therapeutically effective co-crystals patent.
Big Pharma
Novartis sues Chinese firm over attempts to make generic heart failure drug
30 September 2021   Pharma giant Novartis has filed a patent suit against Crystal Pharmaceuticals after the rival sought to create a generic version of its heart failure drug Entresto.


Editor's picks

Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

Editor's picks

Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024

More on this story

Generics
Novartis vows to challenge heart drug patent loss
11 July 2023   Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.
Generics
Novartis sued over blockbuster heart failure drug
30 August 2022   Pharma company facing lawsuit from two universities | Dispute centres on therapeutically effective co-crystals patent.
Big Pharma
Novartis sues Chinese firm over attempts to make generic heart failure drug
30 September 2021   Pharma giant Novartis has filed a patent suit against Crystal Pharmaceuticals after the rival sought to create a generic version of its heart failure drug Entresto.

More on this story

Generics
Novartis vows to challenge heart drug patent loss
11 July 2023   Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.
Generics
Novartis sued over blockbuster heart failure drug
30 August 2022   Pharma company facing lawsuit from two universities | Dispute centres on therapeutically effective co-crystals patent.
Big Pharma
Novartis sues Chinese firm over attempts to make generic heart failure drug
30 September 2021   Pharma giant Novartis has filed a patent suit against Crystal Pharmaceuticals after the rival sought to create a generic version of its heart failure drug Entresto.

More features

HLK adds CRISPR specialist as partner
Novo Nordisk files fresh lawsuits to intercept Wegovy generics
UPC delivers first 'imminent infringement' decision in biosimilar dispute
AstraZeneca unit draws line under Samsung dispute
Brown Rudnick expands with new partner duo
UPC: First decisions on merits are ‘testimony to judges’ tight case management’
Morgan Lewis adds two partners to London office
UK firm prevails in ‘exceptionally slow’ UPC test case